A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)

Trial Profile

A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Sirukumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms SIRROUND-LTE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Dec 2017 Planned End Date changed from 15 Apr 2020 to 21 Feb 2020.
    • 28 Nov 2017 Planned primary completion date changed from 25 Nov 2019 to 30 Apr 2018.
    • 08 Nov 2017 Results of a pooled safety analysis of five phase III trials (SIRROUND-D, -M, -H, -T and -LTE; n=2926) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top